BAKER FELIX Form SC 13D/A May 20, 2004

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### SCHEDULE 13D Under the Securities Exchange Act of 1934

(Amendment No. 2)

Information to be included in statements filed pursuant to Rule 13d-1(a) and amendments thereto filed pursuant to Rule 13d-2(a)

#### INTRABIOTICS PHARMACEUTICALS, INC.

(Name of Issuer)

#### Common Stock, \$.001 par value

(Title of Class of Securities)

#### 46116T 100

(CUSIP Number)

Leo Kirby 667 Madison Avenue New York, New York 10021 (212) 521-2418

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 5, 2004

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. [\_]

**Note:** Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (the Act ) or otherwise subject to the liabilities of that section of

the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 11 Pages

#### **SCHEDULE 13D**

## **CUSIP No. 46116T 10 0**

# Page 1 of 11 Pages

			<del></del>			
1		NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)				
	Julian C. Bake	r				
2	CHECK THE	APPR	OPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	(a) [ ] (b) [X]		
3	SEC USE ONI	LY				
4	SOURCE OF I	FUND	S (See Instructions)			
	AF					
5	CHECK BOX ITEMS 2(d) or		SCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO	[]		
6	CITIZENSHIP	OR P	LACE OF ORGANIZATION			
	United States					
	JMBER OF SHARES	7	SOLE VOTING POWER -0-			
	NEFICIALLY WNED BY EACH	8	SHARED VOTING POWER 2,088,215			
	EPORTING PERSON WITH	9	SOLE DISPOSITIVE POWER -0-			
	10 SHARED DISPOSITIVE POWER 2,088,215					
11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
2,088,215						
12	СНЕСК ВОХ	IF TH	E AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN	[]		

	SHARES (See Instructions)							
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)							
	32.0%							
14	TYPE OF REPORTING PERSON (See Instructions)							
	IN							

## **SCHEDULE 13D**

# **CUSIP No. 46116T 10 0**

# Page 2 of 11 Pages

1	NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)			
	Felix J. Baker			
2	CHECK THE	APPR	OPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	(a) [ ] (b) [X]
3	SEC USE ONI	LY		
4		FUND	S (See Instructions)	
	AF			
5	CHECK BOX ITEMS 2(d) or		SCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO	[]
6	CITIZENSHIP	OR P	PLACE OF ORGANIZATION	
	United States			
	UMBER OF SHARES	7	SOLE VOTING POWER -0-	
	BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER 2,088,215	
			SOLE DISPOSITIVE POWER -0-	
			SHARED DISPOSITIVE POWER 2,088,215	

11	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	2,088,215					
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)					
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)					
	32.0%					
14	TYPE OF REPORTING PERSON (See Instructions)					
	IN					

# **SCHEDULE 13D**

# **CUSIP No. 46116T 10 0**

# Page 3 of 11 Pages

1	NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)					
	Andrew H. Tis	ch				
2	CHECK THE	APPR	OPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	(a) [ ] (b) [X]		
3	SEC USE ONI	LY				
4	SOURCE OF I	FUND	S (See Instructions)			
	PF					
5	CHECK BOX ITEMS 2(d) or		SCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO	[]		
6	CITIZENSHIP	OR F	PLACE OF ORGANIZATION			
	United States					
NUMBER OF SHARES		7	SOLE VOTING POWER -0-			
BENEFICIALLY OWNED BY EACH		8	SHARED VOTING POWER 8,050			

REPORTING PERSON		9	SOLE DISPOSITIVE POWER -0-	
	WITH		SHARED DISPOSITIVE POWER 8,050	
11	AGGREGATE	E AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	8,050			
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)			
13	3 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)			
	0.2%			
14 TYPE OF REPORTING PERSON (See Instructions)		ING PERSON (See Instructions)		
	IN			

# **SCHEDULE 13D**

## **CUSIP No. 46116T 10 0**

# Page 5 of 11 Pages

1	NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)					
	Daniel R. Tisch					
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	(a) [ ] (b) [X]				
3	SEC USE ONLY					
4	SOURCE OF FUNDS (See Instructions)					
	PF					
5	CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)	[]				
6	CITIZENSHIP OR PLACE OF ORGANIZATION					
	United States					

NUMBER OF SHARES BENEFICIALLY		<b>7 8</b>	SOLE VOTING POWER -0-		
O	OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER 8,050		
			SOLE DISPOSITIVE POWER -0-		
Willi		10	SHARED DISPOSITIVE POWER 8,050		
11	AGGREGATE	E AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		
	8,050				
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)				
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)				
	0.2%				
14	TYPE OF REPORTING PERSON (See Instructions)				
	IN				

# **SCHEDULE 13D**

# **CUSIP No. 46116T 10 0**

# Page 6 of 11 Pages

1	NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (En Only)  James S. Tisch	ntities
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	(a) [ ] (b) [X]
3	SEC USE ONLY	
4	SOURCE OF FUNDS (See Instructions)	
	PF	

5		CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO [ ] ITEMS 2(d) or 2(e)				
6	CITIZENSHIP	OR P	PLACE OF ORGANIZATION			
	United States					
	UMBER OF SHARES	7	SOLE VOTING POWER -0-			
	NEFICIALLY WNED BY EACH	8	SHARED VOTING POWER 8,050			
	REPORTING PERSON WITH  9 SOLE -0-		SOLE DISPOSITIVE POWER -0-			
	*******	10	SHARED DISPOSITIVE POWER 8,050			
11	AGGREGATI	E AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	8,050					
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN  [] SHARES (See Instructions)					
13	PERCENT OF	CLA	SS REPRESENTED BY AMOUNT IN ROW (11)			
	0.2%					
14	TYPE OF REPORTING PERSON (See Instructions)					
	IN					

## **SCHEDULE 13D**

# CUSIP No. 46116T 10 0

# Page 7 of 11 Pages

1	NAMES OF REPORTING PERSONS/I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)						
	Thomas J. Tisch						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)	(a) [ ] (b) [X]					

3	SEC USE ONI	SEC USE ONLY				
4	SOURCE OF I	SOURCE OF FUNDS (See Instructions)				
	PF					
5	CHECK BOX ITEMS 2(d) or		SCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO	[]		
6	CITIZENSHIP	OR F	PLACE OF ORGANIZATION			
	United States					
	JMBER OF SHARES	7	SOLE VOTING POWER -0-			
	NEFICIALLY WNED BY EACH	8	SHARED VOTING POWER 8,050			
	REPORTING PERSON WITH		SOLE DISPOSITIVE POWER -0-			
	WIIII	10	SHARED DISPOSITIVE POWER 8,050			
11	AGGREGATE	E AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON			
	8,050					
12	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions)					
13	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)					
	0.2%					
14	TYPE OF REF	PORT	ING PERSON (See Instructions)			
	IN					

This Amendment No. 2 (the Amendment ) to Schedule 13D is being filed by Julian C. Baker, Felix J. Baker, Andrew H. Tisch, Daniel R. Tisch, James S. Tisch and Thomas J. Tisch (the Reporting Persons ) to amend and supplement the statement on Schedule 13D previously filed by the Reporting Persons. Except as amended and supplemented therein, that statement remains in full force and effect.

#### Item 5. Interest in Securities of the Issuer.

Because of certain business and family relationships among the Reporting Persons, they are filing as if they constitute a group solely for informational purposes. By signing this statement, each Reporting Person agrees that this Statement is filed on his or her behalf. The filing of this statement is not an admission by any Reporting Person that

such Reporting Person and any other Reporting Person or Reporting Persons constitute a group for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder. Each Reporting Person disclaims beneficial ownership of, or a pecuniary interest in, any securities of the Company owned by any other Reporting Person, except to the extent that any beneficial ownership or pecuniary interest is expressly reported herein.

The table below sets forth the aggregate number of shares of Common Stock owned by each of the designated entities, together with the percentage of outstanding shares of Common Stock that such ownership represents, in each case taking into account the shares of Common Stock that each entity has the right to acquire upon conversion of the Series A Preferred Stock and exercise of the Warrants. The ownership percentages are based upon 5,364,383 shares of Common Stock outstanding as of March 31, 2004, as reported by the Company in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2004.

Name of Beneficial Owner	Amount and Nature of Beneficial Ownership	Percent of Class Outstanding
Baker Bros. Investments, L.P.	81,797	15%
Baker Bros. Investments II, L.P.	96,451	18%
Baker/Tisch Investments, L.P.	67,712	12%
Baker Biotech Fund I, L.P.	879,760	151%
Baker Biotech Fund II, L.P.	855,646	147%
Baker Biotech Fund II (Z), L.P.	106,849	20%
Four Partners	8,050	02%
Total	2,096,265	321%

Julian C. Baker and Felix J. Baker, by virtue of their control of entities that have the power to control the investment decisions of Baker Bros. Investments, L.P., Baker Bros. Investments II, L.P., Baker/Tisch Investments, L.P., Baker Biotech Fund I, L.P., Baker Biotech Fund II, L.P. and Baker Biotech Fund II (Z), L.P., may each be deemed to be the beneficial owners of securities held by such entities and may each be deemed to have shared power to vote or direct the vote of and to dispose or direct the disposition of such securities. Each such entity has the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the Company s Common Stock owned beneficially by such entity.

Page 8 of 11 Pages

By virtue of their status as managing trustees of the trusts that are the general partners of Four Partners, a New York general partnership, Andrew H. Tisch, Daniel R. Tisch, James S. Tisch and Thomas J. Tisch may be deemed to have shared beneficial ownership of securities held by Four Partners and shared power to vote or direct the vote of and to dispose or direct the disposition of such securities.

During the 60 days preceding the date hereof, the following purchases of Common Stock were effected by the entities noted below with broker dealers in the over the counter market.

	Number of		
Name	Date	Shares	Price/Share
Baker Bros. Investments, L.P.	05/05/04	22,092	\$13.00
Baker Bros. Investments II, L.P.	05/05/04	21,304	\$13.00
Baker Biotech Fund I, L.P.	05/05/04	209,608	\$13.00

	Number of		
Name	Date	Shares	Price/Share
Baker Biotech Fund II, L.P.	05/05/04	196,266	\$13.00
Baker Biotech Fund II (Z), L.P.	05/05/04	25,730	\$13.00

The entities noted below also received dividends in shares of Common Stock that were paid by the Company to all holders of Series A Preferred Stock during the 60 days preceding the date hereof.

Name	Date	Number of Shares
Baker Bros. Investments, L.P.	04/15/04	60
Baker Bros. Investments II, L.P.	04/15/04	72
Baker/Tisch Investments, L.P.	04/15/04	97
Baker Biotech Fund I, L.P.	04/15/04	679
Baker Biotech Fund II, L.P.	04/15/04	679
Baker Biotech Fund II (Z), L.P.	04/15/04	84

#### Item 7. Material to Be Filed as Exhibits.

Exhibit 1 Agreement regarding the joint filing of this statement.

Page 9 of 11 Pages

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 20, 2004

By:	/s/ Julian C. Baker	
	Julian C. Baker	
By:	/s/ Felix J. Baker	
	Felix J. Baker	
By:	/s/ Andrew H. Tisch	
	Andrew H. Tisch	
_		

By: /s/ Daniel R. Tisch

Daniel R. Tisch

By: /s/ James S. Tisch

James S. Tisch

By: /s/ Thomas J. Tisch

Thomas J. Tisch

Page 10 of 11 Pages